WO2000046376A3 - Partikel zur gentherapie - Google Patents

Partikel zur gentherapie Download PDF

Info

Publication number
WO2000046376A3
WO2000046376A3 PCT/DE2000/000363 DE0000363W WO0046376A3 WO 2000046376 A3 WO2000046376 A3 WO 2000046376A3 DE 0000363 W DE0000363 W DE 0000363W WO 0046376 A3 WO0046376 A3 WO 0046376A3
Authority
WO
WIPO (PCT)
Prior art keywords
particles
protein
domain
virus
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE2000/000363
Other languages
English (en)
French (fr)
Other versions
WO2000046376A2 (de
Inventor
Eberhard Hildt
Peter Hofschneider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US09/890,752 priority Critical patent/US7018826B1/en
Priority to EP00909000A priority patent/EP1165797B1/de
Priority to DE50015272T priority patent/DE50015272D1/de
Priority to DK00909000T priority patent/DK1165797T3/da
Publication of WO2000046376A2 publication Critical patent/WO2000046376A2/de
Publication of WO2000046376A3 publication Critical patent/WO2000046376A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10141—Use of virus, viral particle or viral elements as a vector
    • C12N2730/10143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C12N2810/405—Vectors comprising RGD peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Die vorliegende Erfindung betrifft Partikel, umfassend: (a) eine Proteinhülle mit einem Fusionsprotein, das ein Virus-Protein, ein Zellpermeabilität-vermittelndes Peptid und eine heterologe zellspezifische Bindungsstelle umfasst, und (b) eine in der Proteinhülle vorliegende Nukleinsäure, die Sequenzen für ein Virus-spezifisches Verpackungssignal und ein Struktur-Gen aufweist. Bevorzugt sind Hepatitis B Viruspartikel, die ein rekombinantes LHB (large surface protein) exprimieren, bei dem die PreS1 Domaine gegen die alpha5betal Integrin-bindende Domaine von Fibronektin ausgetauscht wurde, bzw. Hepatitis B Viruspartikel, die ein Fusionsprotein enthalten, das die PreS2 Domaine, das HBV core Protein und die alpha5betal Domaine umfassen um eine veränderte gewebespezifische Anheftung der Viruspartikel zu erzielen.
PCT/DE2000/000363 1999-02-05 2000-02-04 Partikel zur gentherapie Ceased WO2000046376A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US09/890,752 US7018826B1 (en) 1999-02-05 2000-02-04 Particles for gene therapy
EP00909000A EP1165797B1 (de) 1999-02-05 2000-02-04 Partikel zur gentherapie
DE50015272T DE50015272D1 (de) 1999-02-05 2000-02-04 Partikel zur gentherapie
DK00909000T DK1165797T3 (da) 1999-02-05 2000-02-04 Partikler til genterapi

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19904800.2 1999-02-05
DE19904800A DE19904800C1 (de) 1999-02-05 1999-02-05 Partikel zur Gentherapie

Publications (2)

Publication Number Publication Date
WO2000046376A2 WO2000046376A2 (de) 2000-08-10
WO2000046376A3 true WO2000046376A3 (de) 2000-11-16

Family

ID=7896602

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2000/000363 Ceased WO2000046376A2 (de) 1999-02-05 2000-02-04 Partikel zur gentherapie

Country Status (9)

Country Link
US (1) US7018826B1 (de)
EP (1) EP1165797B1 (de)
AT (1) ATE402261T1 (de)
CY (1) CY1107431T1 (de)
DE (2) DE19904800C1 (de)
DK (1) DK1165797T3 (de)
ES (1) ES2310988T3 (de)
PT (1) PT1165797E (de)
WO (1) WO2000046376A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19850718C1 (de) 1998-11-03 2000-05-18 Hildt Eberhardt Zellpermeabilität-vermittelndes Polypeptid
JP2003286199A (ja) * 2002-03-29 2003-10-07 Japan Science & Technology Corp タンパク質中空ナノ粒子を用いる肝臓疾患治療用薬剤
US8101189B2 (en) 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
JP4953570B2 (ja) * 2002-07-05 2012-06-13 フォリア バイオテック インコーポレイテッド アジュバントウィルス粒子
DE10240894A1 (de) * 2002-09-04 2004-03-11 Procom Biotechnologische Produktions Gmbh Verstärkung der Resorption von Subtanzen über die Haut und Schleimhaut
KR101253261B1 (ko) * 2011-05-11 2013-04-10 한국과학기술연구원 ｓｉＲＮＡ 의 전달을 위한 재조합 단백질 및 이를 포함하는 조성물
CN108611395A (zh) * 2016-12-12 2018-10-02 中山大学 一种抗人乙肝病毒药物的筛选方法
EP4021923A1 (de) 2019-08-29 2022-07-06 VIR Biotechnology, Inc. Hepatitis-b-virus-impfstoffe

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020221A1 (en) * 1992-04-03 1993-10-14 Young Alexander T Gene therapy using targeted viral vectors
WO1997024453A1 (en) * 1995-12-28 1997-07-10 Chiron Corporation Receptor specific chimeric viral surface polypeptides for viral and particle incorporation and internalization in target cells

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19850718C1 (de) 1998-11-03 2000-05-18 Hildt Eberhardt Zellpermeabilität-vermittelndes Polypeptid

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020221A1 (en) * 1992-04-03 1993-10-14 Young Alexander T Gene therapy using targeted viral vectors
WO1997024453A1 (en) * 1995-12-28 1997-07-10 Chiron Corporation Receptor specific chimeric viral surface polypeptides for viral and particle incorporation and internalization in target cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DMITRIEV I. ET AL.: "An Adenovirus Vector with Genetically Modified Fibers Demonstrates Expanded Tropism via Utilization of a Coxsackievirus and Adenovirus Receptor-Independent Cell Entry Mechanism", JOURNAL OF VIROLOGY, vol. 72, no. 12, December 1998 (1998-12-01), pages 9706 - 9713, XP002144482 *
OESS S. ET AL.: "Novel cell permeable motif derived from the PreS2-domain of hepatitis-B virus surface antigens", GENE THERAPY, vol. 7, no. 9, May 2000 (2000-05-01), pages 750 - 758, XP000925809 *
SCHODEL F ET AL: "Hybrid hepatitis B virus core antigen as a vaccine carrier moiety: I. Presentation of foreign epitopes", JOURNAL OF BIOTECHNOLOGY, vol. 44, no. 1, 26 January 1996 (1996-01-26), pages 91 - 96, XP004036853, ISSN: 0168-1656 *

Also Published As

Publication number Publication date
DK1165797T3 (da) 2008-11-24
ES2310988T3 (es) 2009-02-01
WO2000046376A2 (de) 2000-08-10
CY1107431T1 (el) 2012-12-19
ATE402261T1 (de) 2008-08-15
DE50015272D1 (de) 2008-09-04
EP1165797A2 (de) 2002-01-02
US7018826B1 (en) 2006-03-28
DE19904800C1 (de) 2001-02-08
PT1165797E (pt) 2008-10-30
EP1165797B1 (de) 2008-07-23

Similar Documents

Publication Publication Date Title
Yeh et al. The arginine-rich domain of hepatitis B virus precore and core proteins contains a signal for nuclear transport
Bruss et al. Formation of transmembraneous hepatitis B e-antigen by cotranslational in vitro processing of the viral precore protein
Bruss et al. Functions of the internal pre-S domain of the large surface protein in hepatitis B virus particle morphogenesis
WO2005067478A3 (en) Recombinant icosahedral virus like particle production in pseudomonads
PL352332A1 (en) Expression and export of interferon-alpha proteins as fc fusion proteins
WO2000073316A3 (en) Virus immunologic determinants
AU2347997A (en) Synthesis and purification of hepatitis c virus-like particles
ATE318896T1 (de) Rekombinante rna-replikase von hepatitis-c-virus
EP0291586A2 (de) Rekombinantes Hepatitis-B-Oberflächenantigen und dieses enthaltender Impfstoff
WO2000046376A3 (de) Partikel zur gentherapie
WO1999020766A3 (en) NOVEL MODIFIED NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING mRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS
WO2000011033A3 (en) Expression and export of angiostatin and endostatin as immunofusins
WO2001021796A3 (en) Gl50 molecules and uses therefor
WO2000077233A3 (en) Complement-resistant non-mammalian dna viruses and uses thereof
Chang et al. Functional domains of delta antigens and viral RNA required for RNA packaging of hepatitis delta virus
WO2001038358A3 (en) Hbv/hcv virus-like particle
JP2003514576A5 (de)
WO2001066566A3 (fr) Particules pseudovirales de rotavirus et leur utilisation pour vectoriser des proteines ou des acides nucleiques
JO1885B1 (en) A method for purifying surface serum for viral hepatitis B, consisting of Bryce 2 peptide
ES2225502T3 (es) Arn modificado en nodavirus para la administracion de genes.
IL138804A0 (en) Hepatitis c virus ns5b nucleic acids and proteins
WO2002010417A3 (en) Methods and compositions for the construction and use of viral envelops as display particles
WO2000066743A3 (en) Viral expression vectors
WO2003004600A3 (en) Improvement of viral uptake into cells and tissues
Yu et al. Engineered bio‐nanocapsules, the selective vector for drug delivery system

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000909000

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09890752

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000909000

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2000909000

Country of ref document: EP